Back to research
Data as of 7 min read

Scaled to 227 Staff on UK NHS Right-to-Choose Referrals Before Budget Caps Halved Checkout Visits

Co-founded by former NHS director Mark Pattison and Bobby Pratap under UK firm Centre for ADHD Research & Excellence Ltd, Care ADHD (now redirecting to noodlehealth.com as 'Noodle, formerly Care ADHD') scaled to 227 employees by soaking up spillover from jammed UK ADHD waitlists. Combining private fees (£399 assessment / £599 titration) with NHS Right to Choose GP referrals, it served thousands in year one and targeted 8,000 assessments/month—until 2026 NHS ICB budget caps and 22–32 week titration delays halved checkout traffic from 29.5K/mo to 14.7K in July.

Who it is for
UK adults and children facing multi-year public NHS ADHD waitlists—accessed either free via England's NHS Right to Choose GP referrals or via private self-pay.
How it charges
Self-pay rates are £399 for diagnostic assessment, £599 for 12-week medication titration, and £230 for the app course; England patients qualify free under NHS Right to Choose (per-case NHS tariff undisclosed).
01

Executive Summary

What this business is

Customers

UK adults and children facing multi-year public NHS ADHD waitlists—accessed either free via England's NHS Right to Choose GP referrals or via private self-pay.

Offering

CQC-regulated, consultant-psychiatrist-led ADHD and autism assessment, diagnosis, medication titration, and prescribing service for adults and under-18s, backed by a free online screener and companion app course.

Business model

Institutional healthcare-provider scaling powered by NHS Right to Choose public reimbursement contracts, GP patient-directed referrals, and private-pay clinics.

Pricing

Self-pay rates are £399 for diagnostic assessment, £599 for 12-week medication titration, and £230 for the app course; England patients qualify free under NHS Right to Choose (per-case NHS tariff undisclosed).

Takeoff mode
NHS Policy Referral Spillover

Post-2023 UK ADHD demand overwhelmed legacy providers like Psychiatry-UK with massive backlogs. Former NHS director Mark Pattison left the NHS mid-2024 to build a CQC-regulated alternative promising dramatically shorter wait times—leveraging England's 'Right to Choose' rule that lets patients instruct their GP to refer them to accredited private providers at NHS expense.

Although formal financials aren't published, combining £399 assessments + £599 titrations with 'thousands of patients in Year 1' and an 8,000/month assessment target implies tens of millions GBP in annualized potential (inferred), supporting 227 employees. However, checkout visits halving from 29.5K/mo (Apr–Jun) to 14.7K (Jul) reveals sharp pressure on self-pay momentum.

Operated by London-based Centre for ADHD Research & Excellence Ltd (Co. 14535089, incorporated ~Dec 2022) and led by founder Mark Pattison (ex-NHS director) with Deputy CEO & Co-founder Bobby Pratap. Noticeably, careadhd.co.uk now redirects to noodlehealth.com, branded as 'Noodle, formerly Care ADHD'.

Preparing your reading

A work in progress.

2026.11.08 · V0.4

Refined product categories and extension rankings. Added one-line Agent setup and three membership options.